Nature Immunology, volume 23, issue 2, pages 186-193

The T cell immune response against SARS-CoV-2

Publication typeJournal Article
Publication date2022-02-01
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor30.5
ISSN15292908, 15292916
Immunology
Immunology and Allergy
Abstract
The adaptive immune response is a major determinant of the clinical outcome after SARS-CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and correlate with protection but are relatively impaired in severe disease and are associated with intense activation and lymphopenia. A subset of T cells primed against seasonal coronaviruses cross reacts with SARS-CoV-2 and may contribute to clinical protection, particularly in early life. T cell memory encompasses broad recognition of viral proteins, estimated at around 30 epitopes within each individual, and seems to be well sustained so far. This breadth of recognition can limit the impact of individual viral mutations and is likely to underpin protection against severe disease from viral variants, including Omicron. Current COVID-19 vaccines elicit robust T cell responses that likely contribute to remarkable protection against hospitalization or death, and novel or heterologous regimens offer the potential to further enhance cellular responses. T cell immunity plays a central role in the control of SARS-CoV-2 and its importance may have been relatively underestimated thus far. Paul Moss reviews the current knowledge of T cell immunity in the control of SARS-CoV-2.

Top-30

Citations by journals

20
40
60
80
100
120
Frontiers in Immunology
103 publications, 11.68%
Vaccines
67 publications, 7.6%
Nature Communications
29 publications, 3.29%
Viruses
27 publications, 3.06%
Vaccine
24 publications, 2.72%
Scientific Reports
14 publications, 1.59%
International Journal of Molecular Sciences
11 publications, 1.25%
iScience
11 publications, 1.25%
npj Vaccines
9 publications, 1.02%
Journal of Medical Virology
9 publications, 1.02%
EBioMedicine
9 publications, 1.02%
Human Vaccines and Immunotherapeutics
8 publications, 0.91%
Journal of Infectious Diseases
8 publications, 0.91%
Pathogens
7 publications, 0.79%
Microbiology spectrum
6 publications, 0.68%
Journal of Clinical Medicine
6 publications, 0.68%
Emerging Microbes and Infections
6 publications, 0.68%
Nature Immunology
6 publications, 0.68%
PLoS ONE
5 publications, 0.57%
Heliyon
5 publications, 0.57%
PLoS Pathogens
5 publications, 0.57%
Microorganisms
5 publications, 0.57%
ImmunoHorizons
4 publications, 0.45%
Biomedicines
4 publications, 0.45%
Diagnostics
4 publications, 0.45%
Cells
4 publications, 0.45%
Cell Reports Medicine
4 publications, 0.45%
Cell Reports
4 publications, 0.45%
Expert Review of Vaccines
4 publications, 0.45%
20
40
60
80
100
120

Citations by publishers

20
40
60
80
100
120
140
160
Multidisciplinary Digital Publishing Institute (MDPI)
157 publications, 17.8%
Elsevier
151 publications, 17.12%
Springer Nature
125 publications, 14.17%
Frontiers Media S.A.
118 publications, 13.38%
Cold Spring Harbor Laboratory
93 publications, 10.54%
Wiley
38 publications, 4.31%
Oxford University Press
27 publications, 3.06%
Taylor & Francis
19 publications, 2.15%
American Society for Microbiology
14 publications, 1.59%
Wolters Kluwer Health
12 publications, 1.36%
Public Library of Science (PLoS)
10 publications, 1.13%
BMJ
8 publications, 0.91%
American Association for the Advancement of Science (AAAS)
7 publications, 0.79%
American Chemical Society (ACS)
6 publications, 0.68%
The American Association of Immunologists
6 publications, 0.68%
Research Square Platform LLC
5 publications, 0.57%
American Society for Clinical Investigation
4 publications, 0.45%
SAGE
4 publications, 0.45%
American Society of Hematology
4 publications, 0.45%
Mary Ann Liebert
3 publications, 0.34%
American Academy of Pediatrics
2 publications, 0.23%
Thieme
2 publications, 0.23%
Korean Academy of Medical Sciences
2 publications, 0.23%
Saint Petersburg Pasteur Institute
2 publications, 0.23%
Eco-Vector LLC
2 publications, 0.23%
PeerJ
2 publications, 0.23%
Dove Medical Press
2 publications, 0.23%
XMLink
2 publications, 0.23%
Walter de Gruyter
1 publication, 0.11%
20
40
60
80
100
120
140
160
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Moss P. The T cell immune response against SARS-CoV-2 // Nature Immunology. 2022. Vol. 23. No. 2. pp. 186-193.
GOST all authors (up to 50) Copy
Moss P. The T cell immune response against SARS-CoV-2 // Nature Immunology. 2022. Vol. 23. No. 2. pp. 186-193.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41590-021-01122-w
UR - https://doi.org/10.1038/s41590-021-01122-w
TI - The T cell immune response against SARS-CoV-2
T2 - Nature Immunology
AU - Moss, P.
PY - 2022
DA - 2022/02/01 00:00:00
PB - Springer Nature
SP - 186-193
IS - 2
VL - 23
SN - 1529-2908
SN - 1529-2916
ER -
BibTex |
Cite this
BibTex Copy
@article{2022_Moss,
author = {P. Moss},
title = {The T cell immune response against SARS-CoV-2},
journal = {Nature Immunology},
year = {2022},
volume = {23},
publisher = {Springer Nature},
month = {feb},
url = {https://doi.org/10.1038/s41590-021-01122-w},
number = {2},
pages = {186--193},
doi = {10.1038/s41590-021-01122-w}
}
MLA
Cite this
MLA Copy
Moss, P.. “The T cell immune response against SARS-CoV-2.” Nature Immunology, vol. 23, no. 2, Feb. 2022, pp. 186-193. https://doi.org/10.1038/s41590-021-01122-w.
Found error?